AstraZeneca: Tagrisso Met Primary Endpoint in Lung Cancer Trial

By Razak Musah Baba

LONDON--AstraZeneca PLC's (AZN.LN) Tagrisso drug met its primary endpoint in Phase III 2nd-line lung cancer trial, the pharmaceutical company said Monday.

The research-based biopharmaceutical company said the Phase III AURA3 trial met its primary endpoint, demonstrating superior progression-free survival compared with standard platinum-based doublet chemotherapy.

"These results confirm Tagrisso as a meaningful alternative to benefit EGFR T790M lung cancer patients. The AURA3 results demonstrate the benefits of our science-led approach that enabled the rapid development of Tagrisso as a targeted treatment to address the most common cause of resistance to a first-generation EGFR-TKI for patients with metastatic EGFR-mutant lung cancer," said Sean Bohen, chief medical officer.

"We remain committed to exploring the potential of Tagrisso to further extend its reach and help meet patient need," Mr. Bohen said.

AstraZeneca is committed to exploring the full potential of Tagrisso as monotherapy and in combination, for patients with lung cancer.

Write to Razak Musah Baba at [e-mail]; Twitter: @Raztweet

(END) Dow Jones Newswires

July 18, 2016 02:31 ET (06:31 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.